| Similar Articles |
|---|
 |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline.   |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
November 23, 2010
Brian Orelli |
Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients. |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
November 17, 2009
Dave Mock |
A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
November 1, 2006
Brian Lawler |
Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
January 11, 2012
Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running. |
The Motley Fool
August 18, 2011
Brian Orelli |
A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months. |
The Motley Fool
November 12, 2009
Kris Eddy |
Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy. |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
Chemistry World
October 23, 2014
Rebecca Trager |
Amgen seeks injunction to protect patents The US biopharmaceutical company Amgen has filed a patent infringement lawsuit against Sanofi and Regeneron in the US District Court of Delaware. |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
The Motley Fool
July 23, 2011 |
Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
The Motley Fool
January 4, 2008
Brian Orelli |
Rabid Growth at Crucell Crucell signs a marketing agreement with Sanofi-Aventis to market Crucell's rabies treatment; who benefits more? |
The Motley Fool
November 24, 2009
Brian Orelli |
4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
Regeneron: New York State of Mind Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown. |
The Motley Fool
December 30, 2010
Brian Orelli |
2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year. |
The Motley Fool
May 29, 2010
Kris Eddy |
The Motley Fool's Weekly Editors' Picks Netflix hits $100... Orphan drugs equals big opportunity... Investing begins at 65... Garmin's last gasp... |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
The Motley Fool
November 21, 2011
Brian Orelli |
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? |
BusinessWeek
January 9, 2006
Carol Matlack |
Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
August 30, 2010
Brian Orelli |
It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface? |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
December 31, 2010
Brian Orelli |
CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
September 11, 2008
Brian Lawler |
Will a Change Cure Sanofi? The drugmaker charts a different course for its future. |
